CN108624523B - 胚芽乳酸杆菌tci378及其于减脂及改善肠胃功能的应用 - Google Patents
胚芽乳酸杆菌tci378及其于减脂及改善肠胃功能的应用 Download PDFInfo
- Publication number
- CN108624523B CN108624523B CN201810210650.7A CN201810210650A CN108624523B CN 108624523 B CN108624523 B CN 108624523B CN 201810210650 A CN201810210650 A CN 201810210650A CN 108624523 B CN108624523 B CN 108624523B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- composition
- tci378
- food
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 73
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 73
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 73
- 230000007661 gastrointestinal function Effects 0.000 title claims abstract description 20
- 230000004060 metabolic process Effects 0.000 claims abstract description 17
- 230000011759 adipose tissue development Effects 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims description 35
- 239000002207 metabolite Substances 0.000 claims description 29
- 235000013305 food Nutrition 0.000 claims description 24
- 210000000577 adipose tissue Anatomy 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 235000013402 health food Nutrition 0.000 claims description 8
- 235000016709 nutrition Nutrition 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 235000015872 dietary supplement Nutrition 0.000 claims description 6
- 235000013376 functional food Nutrition 0.000 claims description 6
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 26
- 210000001789 adipocyte Anatomy 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 19
- 239000002775 capsule Substances 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 238000012423 maintenance Methods 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108091006300 SLC2A4 Proteins 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 230000013872 defecation Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 229920002477 rna polymer Polymers 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 101100244177 Caenorhabditis elegans plin-1 gene Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 235000021109 kimchi Nutrition 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 101150047829 plin-1 gene Proteins 0.000 description 4
- 210000003705 ribosome Anatomy 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- -1 and thereafter Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 235000019625 fat content Nutrition 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 210000000229 preadipocyte Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- 102000001406 Perilipin Human genes 0.000 description 2
- 108060006002 Perilipin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000021108 sauerkraut Nutrition 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241001199075 Dichelostemma capitatum Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 235000021102 Greek yogurt Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000017795 Perilipin-1 Human genes 0.000 description 1
- 108010067162 Perilipin-1 Proteins 0.000 description 1
- 235000010580 Psophocarpus tetragonolobus Nutrition 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003230 hygroscopic agent Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
一种胚芽乳酸杆菌(Lactobacillus plantarum)TCI378,其寄存于德国国家菌种保藏中心(寄存编号为DSM32451),其可减少脂肪形成、增加脂肪代谢及改善胃肠功能。
Description
技术领域
本发明涉及一种新颖的胚芽乳酸杆菌(Lactobacillus plantarum)TCI378。本发明也涉及胚芽乳酸杆菌TCI378及/或其代谢产物的应用,尤其是涉及减少脂肪形成、增加脂肪代谢、使个体不易形成体脂肪、及/或改善胃肠功能的应用。
背景技术
现代人因作息不正常、长期外食、生活压力、缺乏运动等因素,代谢症候群、三高(高血糖、高血压、高血脂)等疾病发生率不断升高。从一开始的胃肠功能变差、新陈代谢变慢,使得每日摄取的热量累积未被消耗、形成脂肪,乃致于后来的便秘、肥胖、慢性病等病症一一浮现,对人们的健康造成明显的威胁。
虽然保持规律运动及多摄取蔬果可达到改善胃肠功能、促进脂肪代谢的效果,但对于忙碌且经常外食的现代人而言,仍需要其他更便利的方案。近年来,与改善胃肠功能、促进脂肪代谢相关的产品(如蔬果酵素)不断推陈出新,益生菌(probiotics)也成为热门的研究方向。
嗜脂益生菌的出现曾为益生菌于减脂的应用带来极大的希望,然而专家后来指出,在目前的研究当中,还未发现依赖消化脂肪以维生的益生菌。存在于人体肠道菌丛中的格兰氏阴性病菌是依赖消化脂肪维生的细菌,当人体摄取过多脂质,格兰氏阴性病菌会大量繁殖,其表面的脂多醣(lipopolysaccharide,LPS)会导致人体产生发炎反应,反而会引起肥胖、糖尿病、心血管疾病,甚至癌症。
乳酸杆菌(Lactobacillus)是存在于人体中的益生菌之一,可用于多种发酵食品的制备,且目前已有许多乳酸杆菌属的菌株已被美国食品药物管理局(Food and DrugAdministration,FDA)分类属于“公认安全(generally recognized as safe,GRAS)”的食品添加物。
本发明人自韩国泡菜中筛选出一种新颖胚芽乳酸杆菌TCI378菌株,且通过实验发现,该菌株及其代谢物具有减少脂肪形成、增加脂肪代谢及改善胃肠功能的功效。
发明内容
本发明的一目的,在于提供一种胚芽乳酸杆菌TCI378,其寄存于德国国家菌种保藏中心(DSMZ)(寄存编号为DSM32451)。
本发明的另一目的,在于提供一种组合物,其包含胚芽乳酸杆菌TCI378及其代谢产物。
本发明的又一目的,在于提供一种使用胚芽乳酸杆菌TCI378及其代谢产物于制备一组合物的用途。
上述根据本发明所提供的组合物用于以下的至少一者:减少脂肪形成、增加脂肪代谢、使个体不易形成体脂肪及改善胃肠功能。上述根据本发明所提供的组合物为一医药组合物、食品组合物或饲料组合物。较佳地,该医药组合物呈口服剂型。该食品组合物为一健康食品、保健食品、机能性食品、营养补充品或特殊营养食品。
本发明的详细技术内容及部分具体实施态样,将描述于以下内容中,以供本发明所属领域技术人员据以明了本发明的特征。
附图说明
图1至图4分别显示脂肪细胞经过不同培养液处理之后的结果,其中,图1显示细胞经处理后的染色照片图且箭头所指深色区域为油滴,图2显示以控制组为基准的各组细胞的脂质相对含量(**表示与控制组有显著差异,p<0.01;##表示与空白组有显著差异,p<0.01),图3显示以控制组为基准的各组细胞的PLIN1基因表现量(*表示与控制组有显著差异,p<0.05;**表示与控制组有显著差异,p<0.01;#表示与空白组有显著差异,p<0.05),图4显示以控制组为基准的各组细胞的GLUT4基因表现量(**表示与控制组有显著差异,p<0.01;#表示与空白组有显著差异,p<0.05),且其中,控制组仅以脂肪细胞维持培养液进行培养,空白组以含有1%MRS培养液的脂肪细胞维持培养液进行培养,TCI378组则使用含有1%TCI378样品的脂肪细胞维持培养液进行培养;
图5至图9显示胚芽乳酸杆菌TCI378的减脂效益,分别显示受试者于第0天(即,服用含有胚芽乳酸杆菌TCI378的胶囊以前)及第14天(即,连续服用该胶囊14天后)的全身体脂率(图5,*表示与第0天有显著差异,p<0.05)、躯干体脂率(图6,*表示与第0天有显著差异,p<0.05)、体重(图7,**表示与第0天有显著差异,p<0.01)、腰围(图8,*表示与第0天有显著差异,p<0.05)、以及BMI值(图9,**表示与第0天有显著差异,p<0.01);以及
图10胚芽乳酸杆菌TCI378的改善肠胃功能效益,显示受试者于第0天及第14天时的排便情形。
具体实施方式
以下将描述根据本发明的部分具体实施态样;但,在不背离本发明精神下,本发明还可以多种不同形式的态样来实践,不应将本发明保护范围解释为限于说明书所陈述的。此外,除非文中有另外说明,于本说明书中(尤其是在权利要求书中)所使用的“一”、“该”及类似用语应理解为包含单数及复数形式;所谓“个体”是指动物,该动物可以为哺乳动物(例如:人类)或非哺乳动物(例如:禽、鸟)。
韩国泡菜被美国健康专业月刊《健康(Health)》评选为世界五大健康食品之一,杂志中描述韩国泡菜不仅含有维生素A、B及C,更含有乳酸杆菌,故与日本大豆、西班牙橄榄油、希腊酸奶以及印度扁豆一同被评选为世界五大健康食品。
本发明人自韩国泡菜中筛选出一新颖菌株,经16S核糖体核糖核酸(16S rRNA)序列分析,依亲缘关系鉴定为Lactobacillus plantarum(中文名称为胚芽乳酸杆菌株或植物乳酸杆菌),且经命名为Lactobacillus plantarum TCI378(以下称为胚芽乳酸杆菌TCI378),其寄存于德国国家菌种保藏中心(DSMZ)(寄存编号为DSM32451)。该胚芽乳酸杆菌TCI378具有如SEQ ID NO:1所示的16S核糖体核糖核酸(16S rRNA)片段。
本发明人研究发现,胚芽乳酸杆菌TCI378及/或其代谢产物具有减少脂肪形成、增加脂肪代谢以及改善胃肠功能的功效。因此,本发明提供一种胚芽乳酸杆菌TCI378、一种包含胚芽乳酸杆菌TCI378及/或其代谢产物的组合物以及一种使用胚芽乳酸杆菌TCI378及/或其代谢产物于制备一组合物的用途,其中,该组合物可用于以下的至少一者:减少脂肪形成、增加脂肪代谢、使个体不易形成体脂肪及改善胃肠功能。
根据本发明,所采用的胚芽乳酸杆菌TCI378的代谢产物可以是通过在适于胚芽乳酸杆菌TCI378生长的环境下进行培养所产生的。例如:先以适当的培养液对胚芽乳酸杆菌TCI378进行培养,其后,视需要地去除前述培养液中的菌体等固体物,以获得含有代谢产物的液体。
可选用任意合宜的培养液以进行胚芽乳酸杆菌TCI378的培养,以提供所欲的代谢产物,只要该培养液可提供胚芽乳酸杆菌TCI378生长、代谢所需养分(如酵母菌萃取物、蛋白质及葡萄糖)与条件(如酸碱值)即可。此外,胚芽乳酸杆菌TCI378的培养时间也无特殊限制,只要足以使胚芽乳酸杆菌TCI378完成至少一次代谢循环即可。举例言之,于本发明一具体实施例中,以MRS培养液对胚芽乳酸杆菌TCI378进行培养,历时18小时,使菌株进行代谢作用并产生代谢产物。
于本发明中,可直接使用经历胚芽乳酸杆菌TCI378的代谢循环的含胚芽乳酸杆菌TCI378与代谢产物的培养液,或使用经移除胚芽乳酸杆菌TCI378等固体物的含代谢产物的液体。可采用任何合宜的操作以移除固体物,只要对培养后所产生的代谢产物的所欲效益没有不利的影响即可。一般而言,采用物理手段以移除固体物,该物理手段包括,例如:离心分离、滤膜过滤、沉淀倾析等操作。视需要地,可重复或合并进行前述物理操作,以尽可能去除培养液中的菌体等固体物。
根据本发明的应用所提供的医药组合物可呈任何合宜的形式,并无特殊限制,端视所欲的用途而呈对应的合宜剂型。举例言之,但不以此为限,该医药组合物可以口服的投药方式施用至有需要的个体上。其中,视用途而定,可选用合宜的载剂以提供该医药组合物,其中,该载剂包括赋形剂、稀释剂、辅助剂、安定剂、吸收延迟剂、崩散剂、增溶剂、乳化剂、抗氧化剂、黏合剂、结合剂、增黏剂、分散剂、悬浮化剂、润滑剂、吸湿剂等。
于根据本发明所提供的医药组合物中可含有任何不会不利影响活性成分(即,胚芽乳酸杆菌TCI378及其代谢产物)的所欲效益的医药上可接受的载剂,例如:水、食盐水、葡萄糖(dextrose)、甘油、乙醇或其类似物、纤维素、淀粉、糖膨润土(sugar bentonite)及前述的组合。可利用任何合宜的方法,将该医药组合物以适于口服投药的剂型提供,例如:锭剂(例如糖衣锭)、丸剂、胶囊剂、颗粒剂、散剂、流浸膏剂、溶液剂、糖浆剂、悬液剂、酊剂等。
根据本发明所提供的医药组合物可以一日一次、一日多次或数日一次等不同投药频率施用,端视投予个体的需求、年龄、体重及健康状况而异。于根据本发明所提供的医药组合物中,可视实际应用需求,调整胚芽乳酸杆菌TCI378及/或其代谢产物于组合物中的含量比例。此外,该医药组合物可视需要另外含一或多种其他活性成分,或者与含该一或多种其他活性成分的药物并用,以进一步加强该医药组合物的功效或增加制剂配方的运用灵活性与调配度,只要该其他活性成分对本发明活性成分(即,胚芽乳酸杆菌TCI378及/或其代谢产物)的效益没有不利的影响即可。
根据本发明所提供的食品组合物可以为健康食品、保健食品、机能性食品、营养补充品或特殊营养食品,且可制成例如乳制品、肉类加工品、面包类、面食类、饼干、口含锭、胶囊、果汁类、茶类、运动饮料、营养饮料等产品,但不以此为限。
根据本发明所提供的健康食品、保健食品、机能性食品、营养补充品及特殊营养食品可以一日一次、一日多次或数日一次等不同频率食用,端视投予个体的年龄、体重及健康状况而异。也可针对特定族群的需要,调整据本发明所提供的健康食品、保健食品、机能性食品、营养补充品及特殊营养食品中的胚芽乳酸杆菌TCI378及/或其代谢产物的含量,例如,调整至每日应服用的量。
针对根据本发明所提供的健康食品、保健食品、机能性食品、营养补充品及/或特殊营养食品,可于其外包装上标示建议使用量、特定族群(例如高血脂患者、孕妇等)的使用标准及条件、或与其他食品或医药共同服用的建议事项等,以利用户在无医师、药师或相关执事人员的指导下自行服用而无安全虞虑。于根据本发明所提供的食品组合物中,有关该胚芽乳酸杆菌TCI378及/或其代谢产物的态样,如上述说明。
视需要地,可于根据本发明所提供的医药组合物、食品组合物或饲料组合物中另外含有合宜用量的添加剂,例如可提高该医药组合物、食品组合物或饲料组合物于服用时的口适感及视觉感受的调味剂、调色剂、着色剂等,以及可改善该医药组合物、食品组合物或饲料组合物的稳定性及储存性的缓冲剂、保存剂、防腐剂、抗菌剂、抗真菌剂等。
本发明也提供一种减少脂肪形成、增加脂肪代谢、使个体不易形成体脂肪、及/或改善胃肠功能的方法,其包含对一有需要的个体投予一组合物,其中该组合物含有有效量的胚芽乳酸杆菌TCI378及/或其代谢产物。有关该胚芽乳酸杆菌TCI378及/或其代谢产物的态样,也如上述说明。
现以下列实施例进一步例示说明本发明。其中这些实施例仅提供作为说明,而非用以限制本发明的保护范围。本发明保护范围应以权利要求书所界定为准。
实施例
[制备实施例]
A.胚芽乳酸杆菌TCI378的筛选与鉴定
(A-1)筛选
将韩国泡菜的均质物(包含泡菜及酱汁)与MRS培养液(MRS broth)以体积比1:100的比例混合,并置于37℃下进行厌氧培养(氧气浓度低于5%),历时18小时。其后,将前述培养液涂布于MRS固态培养基(MRS agar)上,并置于37℃下进行厌氧培养,以生成不同的菌落。接着,为确保菌株的单一性,使用无菌接种环挑选一菌落,于固态培养基上进行分区划线,再置于37℃的厌氧培养箱中培养直到单一菌落(single colony)出现。
(A-2)鉴定
取(A-1)所分离出的单一菌落的菌株,进行基因族谱分析(phylogeneticanalysis),确认该菌株具有如SEQ ID NO:1所示的16S核糖体核糖核酸(16S rRNA)片段。使用NCBI(National Center for Biotechnology Information)在线数据库进行比对,确认该SEQ ID NO:1与胚芽乳酸杆菌(Lactobacillus plantarum)菌株的16S核糖体核糖核酸(16S rRNA)片段具有约99%的相似度,故依亲缘关系鉴定该标的菌株为胚芽乳酸杆菌,且命名为胚芽乳酸杆菌TCI378。
(A-3)保存
使用液态培养的方式将(A-1)所获得的具单一性的菌株培养于MRS培养液中,以提供菌液,接着于菌液中添加25%的甘油,将所得混合液移至冷冻保存管中后,置于-80℃保存。
B.胚芽乳酸杆菌TCI378的活化与样品制备
(B-1)活化
将存有胚芽乳酸杆菌TCI378菌株的冷冻保存管解冻,以1%的植菌量(约1x104CFU/mL)将TCI378菌株接种于MRS培养液中,并置于37℃下进行厌氧培养,历时18小时,以提供胚芽乳酸杆菌TCI378菌液,供后续实验使用。
(B-2)样品制备
取(B-1)提供胚芽乳酸杆菌TCI378菌液,以1%的植菌量(约1x104CFU/mL)接种于MRS培养液之中,并置于37℃下进行厌氧培养,历时18小时。其后,以5000rpm转速对培养后的菌液进行离心,历时5分钟,再使用0.2μm的滤膜对所获得的上清液进行过滤,所得滤液即为TCI378样品(含有胚芽乳酸杆菌TCI378的代谢产物)。
C.脂肪细胞培养
(C-1)细胞培养液
(1)前脂肪细胞增殖培养液(pre-adipocyte expansion medium):
-90%杜氏改良依格尔培养液(Dulbecco's Modified Eagle's Medium;购自Gibco);
-10%牛血清(Bovine Serum;购自Gibco);以及
-1%盘尼西林-链霉素溶液(Penicillin-streptomycin;购自Gibco)。
(2)分化培养液(differentiationmedium):
-90%杜氏改良依格尔培养液(购自Gibco);
-10%胎牛血清(Fetal Bovine Serum;购自Gibco);
-1%盘尼西林-链霉素溶液(购自Gibco);
-1.0微莫耳/毫升迪皮质醇(Dexamethasone;购自Sigma);
-0.5毫莫耳/毫升甲基异丁基黄嘌呤(Methylisobutylxanthine;购自Sigma);以及
-1.0微克/毫升胰岛素(购自Sigma)。
(3)脂肪细胞维持培养液(adipocyte maintenance medium)
-90%杜氏改良依格尔培养液(购自Gibco);
-10%胎牛血清(Fetal Bovine Serum;购自Gibco);
-1%盘尼西林-链霉素溶液(购自Gibco);以及
-1.0微克/毫升胰岛素(购自Sigma)。
(C-2)脂肪细胞分化
以每孔8x104颗细胞的细胞数,将老鼠纤维母细胞株3T3-L1细胞(购自财团法人食品工业发展研究所,BCRC 60071)种植于24孔盘中,并以(C-1)的前脂肪细胞增殖培养液于37℃培养48小时,其后将细胞培养液替换成(C-1)的分化培养液,再于37℃下培养4天,接下来再将细胞培养液置换成(C-1)的脂肪细胞维持培养液,继续于37℃培养8天,以获得一脂肪细胞,供后续实验使用。
实施例1:胚芽乳酸杆菌TCI378及其代谢产物于减脂的功效
(1-1)细胞处理
取[制备实施例C-2]提供的脂肪细胞,分成三组,并分别以如下表的条件,置于37℃下培养48小时:
组别 | 培养条件 |
控制组 | 脂肪细胞维持培养液 |
空白组 | 脂肪细胞维持培养液+1%MRS培养液 |
TCI378组 | 脂肪细胞维持培养液+1%TCI378样品 |
(1-2)油红O脂肪染色
以磷酸盐缓冲液(PBS)润洗(1-1)提供的各组细胞两次,接着于各组加入1.0毫升的10%甲醛并静置于室温下30分钟,以固定细胞。其后,将甲醛移除并以PBS润洗各组细胞两次,再于各组加入1.0毫升的50%的异丙醇,静置1分钟后将异丙醇移除。最后,于各组加入1.0毫升的油红O溶液,并于室温静置一小时以将油滴染色。移除油红O溶液后,以PBS润洗各组细胞两次,并以显微镜观察脂肪细胞的油滴状况并拍照记录,结果示于图1(箭头所指的深色对比部分即为脂肪油滴)。
待完成上述脂肪细胞油滴的观察与记录后,以100%的异丙醇处理各组细胞10分钟,将堆积的油滴溶出,然后侦测波长于510nm下的吸光值,以检测各组的脂肪含量。最后,以控制组的结果为基准(即,将控制组的脂肪含量设定为1倍),计算其他两组的相对脂肪含量,结果示于图2。
由图1可知,相较于控制组,TCI378组的细胞其油滴明显缩小,空白组细胞的油滴则没有显著变化。由图2可知,无论是相较于控制组或是空白组,TCI378组细胞的脂质含量均下降约15%。前述结果显示,胚芽乳酸杆菌TCI378及/或其代谢产物可有效降低脂肪细胞中的脂质含量。
(1-3)基因表现分析
已知蛋白质Perilipin可保护脂肪细胞油滴不被破坏,若可减少Perilipin的表现量,即可使脂肪细胞的油滴容易被分解,进而增加脂肪代谢。此外,已知GLUT4基因表现增加会影响脂肪细胞对于葡萄糖的吸收,进而产生脂肪酸而导致肥胖,若能减少GLUT4基因表现量,即可减少脂肪形成。为确认胚芽乳酸杆菌TCI378及/或其代谢产物是否具有促进脂肪代谢及/或减少脂肪形成的效果,本实施例进行以下分析,以检测胚芽乳酸杆菌TCI378对PLIN1基因(即,表现Perilipin蛋白的基因)及GLUT4基因表现的影响。
收集(1-1)提供的各组细胞,以核糖核酸纯化套组(RNA purification kit;购自GeneMark)进行RNA萃取,并以反转录酶套组(SuperScriptTM Reverse Transcriptase kit;购自Invitrogen)将该RNA反转录为cDNA。接着,以SYBR Green Master Mix(购自KAPA)及ABI StepOne PlusTM System对前述的cDNA进行qPCR(quantitative polymerase chainreaction),以检测PLIN1基因及GLUT4基因的表现量。以控制组的结果为基准(即,将控制组的基因表现量设定为1倍),计算萃取物组的基因相对表现量。结果示于图3及图4。
由图3及图4可知,无论是相较于控制组或空白组,TCI378组的PLIN1基因及GLUT4基因表现量均有明显较低。
(1-2)及(1-3)的结果显示,本发明的胚芽乳酸杆菌TCI378及/或其代谢产物确实具有减少脂肪形成及增加脂肪代谢的效果,故可降低脂肪细胞中的脂质含量,使个体不易形成体脂肪。
实施例2:胚芽乳酸杆菌TCI378于减脂及改善肠胃功能的功效
招集10位受试者(体脂肪皆大于27、且未服用任何减肥食品或药物者)。于实验开始前(即,服用含有胚芽乳酸杆菌TCI378的胶囊以前),先请各受试者自我评估是否有排便不干净的情形(由没有、偶尔、有时候、总是等选项中进行选择),并测量体重、腰围、BMI值、全身体脂率、躯干体脂率。接着,请受试者于每日午餐过后服用一颗含有胚芽乳酸杆菌TCI378的胶囊(每颗胶囊含有5x109 CFU的胚芽乳酸杆菌TCI378),连续服用14天(即,各受试者服用该胶囊14次)。其后,再次请各受试者评估是否有排便不干净的情形,并测量体重、腰围、BMI值、全身体脂率及躯干体脂率。最后,将10位受试者的体重、腰围、BMI值、全身体脂率及躯干体脂率取平均值,结果示于图5至图9。另一方面,将受试者自我评估的“排便不干净”的结果进行统计,以受试者的总数为基准(即,设为1),计算没有、偶尔、有时候或总是有排便不干净情形的受试者的比例,结果示于图10。
由图5至图9可知,相较于服用含有胚芽乳酸杆菌TCI378的胶囊以前(第0天),受试者于连续服用胶囊14天后(第14天),无论是全身体脂率或是躯干体脂率,均有显著下降的趋势。相较于第0天,受试者的体重、腰围及BMI值也均显著降低。此外,由图10可知,受试者于连续服用含有胚芽乳酸杆菌TCI378的胶囊14天后,排便不干净的情形也有改善的趋势。
上述结果表示,受试者于服用含有胚芽乳酸杆菌TCI378的胶囊后,其脂肪堆积的情形与胃肠功能皆得到改善,进而达到体重、BMI值及腰围均下降的效果。因此,本发明所提供的胚芽乳酸杆菌TCI378及其代谢产物确实可用于以下的至少一者:减少脂肪形成、增加脂肪代谢、使个体不易形成体脂肪及改善胃肠功能。
菌种保藏信息
保藏的生物材料:胚芽乳酸杆菌Lactobacillus plantarum TCI378
保藏机构:德国国家菌种保藏中心DSMZ(Deutsche Sammlung vonMikroorganismen und Zellkulturen)
保藏编号:DSM32451
保藏日期:2017年3月13日
保藏机构地址:Inhoffenstraβe 7 B
38124 Braunschweig
GERMANY。
序列表
<110> 大江生医股份有限公司
<120> 胚芽乳酸杆菌TCI378及其于减脂及改善肠胃功能的应用
<130> RZ18014I
<150> US 62/473,785
<151> 2017-03-20
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1076
<212> DNA
<213> Lactobacillus plantarum
<220>
<221> misc_feature
<222> (118)..(118)
<223> n 为 a、c、g、或 t
<220>
<221> misc_feature
<222> (184)..(184)
<223> n 为 a、c、g、或 t
<400> 1
gctggcggcg tgctatacat gcagtcgaac gaactctggt attgattggt gcttgcatca 60
tgatttacat ttgagtgagt ggcgaactgg tgagtaacac gtgggaaacc tgcccagnag 120
cgggggataa cacctggaaa cagatgctaa taccgcataa caacttggac cgcatggtcc 180
gagnttgaaa gatggcttcg gctatcactt ttggatggtc ccgcggcgta ttagctagat 240
ggtggggtaa cggctcacca tggcaatgat acgtagccga cctgagaggg taatcggcca 300
cattgggact gagacacggc ccaaactcct acgggaggca gcagtaggga atcttccaca 360
atggacgaaa gtctgatgga gcaacgccgc gtgagtgaag aagggtttcg gctcgtaaaa 420
ctctgttgtt aaagaagaac atatctgaga gtaactgttc aggtattgac ggtatttaac 480
cagaaagcca cggctaacta cgtgccagca gccgcggtaa tacgtaggtg gcaagcgttg 540
tccggattta ttgggcgtaa agcgagcgca ggcggttttt taagtctgat gtgaaagcct 600
tcggctcaac cgaagaagtg catcggaaac tgggaaactt gagtgcagaa gaggacagtg 660
gaactccatg tgtagcggtg aaatgcgtag atatatggaa gaacaccagt ggcgaaggcg 720
gctgtctggt ctgtaactga cgctgaggct cgaaagtatg ggtagcaaac aggattagat 780
accctggtag tccataccgt aaacgatgaa tgctaagtgt tggagggttt ccgcccttca 840
gtgctgcagc taacgcatta agcattccgc ctggggagta cggccgcaag gctgaaactc 900
aaaggaattg acgggggccc gcacaagcgg tggagcatgt ggtttaattc gaagctacgc 960
gaagaacctt accaggtctt gacatactat gcaaatctaa gagattagac gttcccttcg 1020
ggacatggat acaggtggtg catggttgtc gtcagctcgt gtcgtgagat gttggg 1076
Claims (10)
1.一种胚芽乳酸杆菌(Lactobacillus plantarum)TCI378,其特征在于,其寄存于德国国家菌种保藏中心(DSMZ),寄存编号为DSM32451。
2.一种组合物,其特征在于,其包含如权利要求1所述的胚芽乳酸杆菌TCI378。
3.一种组合物,其特征在于,其包含如权利要求1所述的胚芽乳酸杆菌及其代谢产物。
4.如权利要求2或3所述的组合物,其特征在于,其用于以下的至少一者:减少脂肪形成、增加脂肪代谢、使个体不易形成体脂肪及改善胃肠功能。
5.如权利要求4所述的组合物,其特征在于,其为一医药组合物、食品组合物或饲料组合物。
6.一种使用如权利要求1所述的胚芽乳酸杆菌TCI378于制备一组合物的用途,其特征在于,该组合物用于以下的至少一者:减少脂肪形成、增加脂肪代谢、使个体不易形成体脂肪及改善胃肠功能。
7.一种使用如权利要求1所述的胚芽乳酸杆菌TCI378及其代谢产物于制备一组合物的用途,其特征在于,该组合物用于以下的至少一者:减少脂肪形成、增加脂肪代谢、使个体不易形成体脂肪及改善胃肠功能。
8.如权利要求6或7所述的用途,其特征在于,该组合物为一医药组合物、食品组合物或饲料组合物。
9.如权利要求8所述的用途,其特征在于,该组合物为医药组合物且呈口服剂型。
10.如权利要求8所述的用途,其特征在于,该组合物为食品组合物,且该食品组合物为一健康食品、保健食品、机能性食品、营养补充品、或特殊营养食品。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762473785P | 2017-03-20 | 2017-03-20 | |
US62/473,785 | 2017-03-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108624523A CN108624523A (zh) | 2018-10-09 |
CN108624523B true CN108624523B (zh) | 2020-10-02 |
Family
ID=63521394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810210650.7A Active CN108624523B (zh) | 2017-03-20 | 2018-03-14 | 胚芽乳酸杆菌tci378及其于减脂及改善肠胃功能的应用 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20180264054A1 (zh) |
JP (1) | JP6630388B2 (zh) |
KR (1) | KR102033031B1 (zh) |
CN (1) | CN108624523B (zh) |
TW (1) | TWI645854B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI725464B (zh) * | 2018-07-03 | 2021-04-21 | 大江生醫股份有限公司 | 減脂之益生菌株及其組合物與用途 |
JP7130287B2 (ja) * | 2018-12-12 | 2022-09-05 | 生合生物科技股▲ふん▼有限公司 | プロバイオティクス組成物の製造方法 |
CN111297912A (zh) * | 2018-12-12 | 2020-06-19 | 生合生物科技股份有限公司 | 胚芽乳酸杆菌twk10制备抗运动后发炎或降体脂组合物的用途 |
KR102177552B1 (ko) * | 2018-12-28 | 2020-11-11 | 건국대학교 산학협력단 | 락토바실러스 프란타룸 g72 균주를 포함하는 위장관 질환 예방 또는 치료용 조성물 |
TWI747280B (zh) * | 2019-05-17 | 2021-11-21 | 大江生醫股份有限公司 | 余甘子萃取發酵物及其製備與應用 |
TWI784326B (zh) * | 2019-10-07 | 2022-11-21 | 大江生醫股份有限公司 | 發酵乳桿菌tci275、其組合物及其用途 |
CN110684701B (zh) * | 2019-11-19 | 2021-02-12 | 西南大学 | 植物乳杆菌s58及其在制备用于缓解肥胖的产品中的应用 |
KR102136335B1 (ko) * | 2020-03-24 | 2020-07-22 | (주)메디톡스 | 간기능 개선 또는 지방축적 억제 미생물 및 그의 용도 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008179595A (ja) * | 2006-12-28 | 2008-08-07 | Nisshin Pharma Inc | 新規乳酸菌および脂肪細胞分化促進用乳酸菌発酵産物 |
CN104073455A (zh) * | 2014-06-18 | 2014-10-01 | 兰州大学 | 一株具有降低胆固醇能力的植物乳杆菌 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100422309C (zh) * | 2004-09-29 | 2008-10-01 | 光明乳业股份有限公司 | 植物乳杆菌st-iii的减肥用途 |
JP2008214253A (ja) | 2007-03-02 | 2008-09-18 | Snow Brand Milk Prod Co Ltd | 内臓脂肪減少剤 |
US20140328814A1 (en) * | 2008-05-13 | 2014-11-06 | Oü Tervisliku Piima Biotehnoloogiate Arenduskeskus (Bio-Competence Centre of | Antimicrobial and antihypertensive probiotic composition, food product and dietary supplement comprising microorganism strain lactobacillus plantarum tensia dsm 21380 and method for suppressing contaminating microbes in a food product |
CN101864375B (zh) * | 2010-01-15 | 2011-11-02 | 吉林省农业科学院 | 一株具有降胆固醇功能的植物乳杆菌及其应用 |
WO2014171478A1 (ja) * | 2013-04-17 | 2014-10-23 | サントリーホールディングス株式会社 | ラクトバチルス属菌含有組成物 |
JP2015008672A (ja) * | 2013-06-28 | 2015-01-19 | 東海漬物株式会社 | 発酵食品とその製造方法、および新規乳酸菌 |
CN103598594B (zh) * | 2013-10-28 | 2015-05-20 | 天津科技大学 | 植物乳杆菌在降血脂和辅助减肥方面的应用 |
JP2015096476A (ja) * | 2013-11-15 | 2015-05-21 | 株式会社東洋新薬 | コラーゲン産生促進用組成物、コラーゲン吸収促進用組成物、抗肥満用組成物 |
US9399048B2 (en) * | 2014-03-05 | 2016-07-26 | Asian Probiotics And Prebiotics Ltd | Lactic acid bacteria and its applications in immunomodulation and anti-inflammation |
WO2015146916A1 (ja) * | 2014-03-24 | 2015-10-01 | 大塚製薬株式会社 | 新規ラクトバチラス・パラカゼイ株 |
KR102125548B1 (ko) * | 2015-02-10 | 2020-06-24 | 주식회사 지니스 | 비만 억제능을 갖는 균주 및 이를 함유하는 약학 조성물 |
CN104928208B (zh) * | 2015-04-30 | 2020-04-10 | 江苏微康生物科技有限公司 | 一种植物乳杆菌Lp90及其筛选方法和应用 |
KR101611834B1 (ko) | 2015-06-08 | 2016-04-14 | 주식회사 쎌바이오텍 | 비만 및 비만으로 야기된 대사성 질환의 예방 또는 치료를 위한 락토바실루스 플란타룸 cbt lp3 균주 및 이를 포함하는 조성물 |
CN105105145B (zh) * | 2015-09-14 | 2022-04-22 | 吉林省命之元生物科技有限公司 | 一株植物乳杆菌及其在制备降血糖血脂的功能性食品中的应用 |
KR101670048B1 (ko) * | 2016-07-26 | 2016-10-27 | (주)메디톡스 | 개체의 지방 함량을 감소시키는 미생물 및 그의 용도 |
-
2018
- 2018-03-06 TW TW107107478A patent/TWI645854B/zh active
- 2018-03-14 CN CN201810210650.7A patent/CN108624523B/zh active Active
- 2018-03-19 JP JP2018051654A patent/JP6630388B2/ja active Active
- 2018-03-19 KR KR1020180031585A patent/KR102033031B1/ko active IP Right Grant
- 2018-03-20 US US15/926,413 patent/US20180264054A1/en not_active Abandoned
-
2020
- 2020-04-21 US US16/854,676 patent/US11273189B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008179595A (ja) * | 2006-12-28 | 2008-08-07 | Nisshin Pharma Inc | 新規乳酸菌および脂肪細胞分化促進用乳酸菌発酵産物 |
CN104073455A (zh) * | 2014-06-18 | 2014-10-01 | 兰州大学 | 一株具有降低胆固醇能力的植物乳杆菌 |
Non-Patent Citations (1)
Title |
---|
Lactobacillus plantarum LG42 isolated from gajami sik-hae decreases body and fat pad weights in diet-induced obese mice;J.-E. Park等;《Journal of Applied Microbiology》;20131231;第116卷;摘要、第145页右栏第1段-第146页左栏第4段、第148页右栏第2段-第154页左栏第1段、第147页表1、第149页表3 * |
Also Published As
Publication number | Publication date |
---|---|
US11273189B2 (en) | 2022-03-15 |
KR20180106987A (ko) | 2018-10-01 |
JP6630388B2 (ja) | 2020-01-15 |
JP2018153182A (ja) | 2018-10-04 |
TW201834675A (zh) | 2018-10-01 |
US20180264054A1 (en) | 2018-09-20 |
TWI645854B (zh) | 2019-01-01 |
US20200254034A1 (en) | 2020-08-13 |
CN108624523A (zh) | 2018-10-09 |
KR102033031B1 (ko) | 2019-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108624523B (zh) | 胚芽乳酸杆菌tci378及其于减脂及改善肠胃功能的应用 | |
TWI678208B (zh) | 新穎的雷曼氏乳桿菌菌株(lactobacillus rhamnosus)與其用於抑制黃嘌呤氧化酶及治療痛風之代謝產物 | |
KR101825836B1 (ko) | 신규한 락토바실러스 플란타룸 Lb41 균주 및 이를 포함하는 당뇨 또는 인슐린 저항성 증후군의 예방 및 치료용 약학적 조성물 | |
AU2016287200B2 (en) | Lactobacillus rhamnosus bacterium for treatment of e.g. bacterial vaginosis | |
KR101379404B1 (ko) | 황금 발효물 및 이를 포함하는 항균 및 면역 증강 조성물 | |
AU2014254813A1 (en) | Composition containing bacterium belonging to genus Lactobacillus | |
KR102543494B1 (ko) | 신규 프로바이오틱스 및 이의 용도 | |
US20130309212A1 (en) | Lactobacillus salivarius and method for preparing metabolite thereof, composition of lactobacillus salivarius and metabolite thereof and use of the composition | |
JP2013116089A (ja) | 抗ヘリコバクター・ピロリ効果を有する乳酸菌株、その乳酸菌株を含む抗ヘリコバクター・ピロリ剤、及びその乳酸菌株を含む飲食品 | |
KR20130084887A (ko) | 오미자 발효물 및 이를 포함하는 항균 및 면역 증강 조성물 | |
KR102037897B1 (ko) | 케피어 유래 유산균 및 포도씨 분말을 포함하는 비만의 예방 또는 치료용 조성물 | |
TWI764295B (zh) | 加氏乳桿菌tci943或其代謝產物及其用於改善肌膚狀況的用途 | |
JPH0930981A (ja) | 免疫賦活組成物 | |
KR20180040894A (ko) | 신규한 락토바실러스 플란타룸 Lb41 균주 및 이를 포함하는 비만의 예방 및 치료용 약학적 조성물 | |
KR20180040899A (ko) | 신규한 락토바실러스 플란타룸 Ln4 균주 및 이를 포함하는 비만의 예방 및 치료용 약학적 조성물 | |
JP7267536B2 (ja) | 乳酸醗酵ニンジンの製造方法 | |
CN113151037A (zh) | 一种香茶菜发酵制剂的制备方法及其抗肿瘤治疗的应用 | |
CN112190644A (zh) | 植物发酵物及其制备方法与用于胃脏保健的用途 | |
CN110839693A (zh) | 吉氏副拟杆菌在预防或治疗肥胖或其相关疾病中的应用 | |
CN112111419B (zh) | 乳双歧杆菌tci604及其代谢产物的应用 | |
EP3313424A1 (en) | Lactobacillus rhamnosus bacterium for treatment of e.g. bacterial vaginosis | |
KR20030080709A (ko) | 약리활성이 우수하고 풍미가 개선된 탕약의 제조방법 | |
KR20240066540A (ko) | 지방합성 억제 효능을 갖는 신규 유산균 락토바실러스 플란타룸 빈스플로라 1712 균주 및 이를 유효성분으로 함유하는 제품 | |
KR20220160773A (ko) | 항염증 활성이 우수한 김치 유래 신균주 락토바실러스 퍼멘텀 및 이를 포함하는 염증성 질환의 예방 또는 치료용 조성물 | |
CN117801977A (zh) | 罗伊氏乳杆菌tci850及其肠道保健、提高免疫力及抗发炎用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190930 Address after: No. 989, Jinge Road, Jinshan Industrial Zone, Jinshan District, Shanghai Applicant after: Baiyuet Biotechnology (Shanghai) Co., Ltd. Address before: Taipei, Taiwan, China, Inner Lake District, 187 Hong Kong Road, 8 floor Applicant before: TCICO Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |